Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.96
-0.83 (-5.61%)
At close: Oct 28, 2025, 4:00 PM EDT
14.22
+0.26 (1.86%)
Pre-market: Oct 29, 2025, 4:32 AM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 403 employees as of December 31, 2024. The number of employees decreased by 123 or -23.38% compared to the previous year.
Employees
403
Change (1Y)
-123
Growth (1Y)
-23.38%
Revenue / Employee
$131,159
Profits / Employee
-$1,191,548
Market Cap
1.50B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | 312 | 42 | 15.56% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NTLA News
- 1 day ago - Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript - Seeking Alpha
- 1 day ago - Intellia pauses late-stage trials of gene-editing treatment after serious liver event - Reuters
- 1 day ago - Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - GlobeNewsWire
- 4 days ago - Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook - Seeking Alpha
- 25 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug - Benzinga
- 4 weeks ago - Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - GlobeNewsWire
- 5 weeks ago - Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis - Seeking Alpha